CD274 and non-small cell lung carcinoma: PD‐1/PD‐L1 expression has been recognized as a suitable predictive biomarker for monitoring tumor response to checkpoint blockade immunotherapy, which has been approved in several types of cancer, such as NSCLC, breast, gastrointestinal, and head and neck cancer [144].